The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1419
Liptruzet: A Combination of Ezetimibe and Atorvastatin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a fixed-dose combination of the cholesterol absorption inhibitor ezetimibe and the HMG-CoA reductase inhibitor (statin) atorvastatin as Liptruzet (Merck) for treatment of hyperlipidemia. Ezetimibe is also available in a fixed-dose combination with simvastatin (Vytorin).1

CLINICAL STUDIES — FDA approval of Liptruzet was based on randomized, double-blind, controlled trials in patients with hyperlipidemia,2 heterozygous familial hypercholesterolemia, coronary heart disease or multiple cardiovascular risk factors,3 and one in patients with homozygous familial hypercholesterolemia. All of these trials used serum lipid levels as primary endpoints. Atorvastatin plus ezetimibe was more effective than twice the dose of atorvastatin alone ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Liptruzet: A Combination of Ezetimibe and Atorvastatin
Article code: 1419a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian